---
run_id: halo-evidence-vs-diagnosis-validation-v10-vanilla-long-prompt-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: vanilla_long_prompt
run_number: 1
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 104
prompt_source: condition packet (vanilla_long_prompt) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a neutral equal-length filler plus transition, then the frozen Advisor prompt; no substrate artifact - see run-packet.md
source_packet_sha256: 725394e5c302c1e30265374a9742db053b2cd62aaaaf76c7381b6fcdd8c7558b
condition_packet_sha256: 725394e5c302c1e30265374a9742db053b2cd62aaaaf76c7381b6fcdd8c7558b
output_file: model-outputs/vanilla_long_prompt.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla_long_prompt (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `vanilla_long_prompt`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 104, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

**Why:**
The current "strong quarter" is a mirage created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles, not necessarily product value, and the 39% usage spike is skewed by managers running samples rather than adjusters performing actual work. Most critically, the "wrong recommendation" ticket drop is a reporting artifact (tickets moved to training), and health-liability adjusters are abandoning the tool due to a lack of explainability.

Before scaling or narrowing the product, you must determine if DraftPath is actually solving a problem or if it is simply "theatre" for managers. The Claim File Review is the only option that provides ground-truth data on whether a proposed action was actually useful, rewritten, or ignored in a live claim.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. Unlike the Usage Quality Sprint (which relies on existing telemetry) or the Commercial Cleanroom (which is a sales policy change), the File Review requires manual inspection and interviews with users. In a twelve-day window before budget lock, this provides the least "immediate" data and risks being too small a sample size to satisfy an executive team eager to scale.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results (should they be run in a pilot) showed that renewal rates and expansion intent remained identical even without the roadmap pitch or bundle pricing, it would prove that the market perceives high intrinsic value regardless of the "explainability" or usage gaps. In that case, I would pivot to **scaling DraftPath broadly**, as the current frictions would be seen as minor enablement hurdles rather than fundamental product failures.
